Loading provider…
Loading provider…
Infectious Disease Physician in Tempe, AZ
NPI: 1265749626Primary Employer
Option Care
optioncareltd.com
HQ Phone
Get MD Atul's Phone Numberphone_androidMobile
Get MD Atul's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
AR State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 59 | 121 |
| 2 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 28 | 48 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 24 | 24 |
Authors: Carolina Schinke, Thomas Eluvathingal, Meera Mohan
Journal: Transpl Infect Dis
Publication Date: 2016-11-10
Skin Lesion with Splenic Microabscesses in a Patient with Acute Myeloid Leukemia.
Lead Sponsor: University of Arkansas
Collaborators: Amgen
Intervention / Treatment: DEVICE: myPRS, DRUG: Induction 1 - MEL-10+CFZ-TD-PACE, DRUG: First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), DRUG: Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), DRUG: Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), DRUG: Consolidation - CFZ-TD-PACE, DRUG: Maintenance - CFZ-R(T)-D
Lead Sponsor: University of Arkansas
Collaborators: Millennium Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Ixazomib
Lead Sponsor: University of Arkansas
Collaborators: National Institutes of Health (NIH)
Intervention / Treatment: DRUG: Bortezomib